Evidence map›Paper›PMID 30949218›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2019

Acute Efficacy of a Traditional Chinese Medicine for Treatment of Frequent Premature Ventricular Contractions in Patients with Concomitant Sinus Bradycardia: Results from a Double-Blind, Placebo-Controlled, Multicentre, Randomized Clinical Trial.

Fengxiang Zhang, Jiangang Zou, Hao Yu, Xiaorong Li, Pipin Kojodjojo, Xin Cai, Shu Zhang, Congxin Huang, Kui Hong, Bo Yu and 14 more

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 18 institutions in 2 countries.

Fengxiang ZhangDepartment of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.ORCID 0000-0003-0125-3926
Jiangang ZouDepartment of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Hao YuDepartment of Statistics of Nanjing Medical University, Nanjing, China.
Xiaorong LiDepartment of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Pipin KojodjojoNational University Heart Centre, National University Hospital, Singapore.
Xin CaiDepartment of Cardiology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Shu ZhangDepartment of Cardiology, Chinese Academy of Medical Sciences Fuwai Cardiovascular Hospital, Beijing, China.
Congxin HuangDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
Kui HongDepartment of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Bo YuDepartment of Cardiology, The First Affiliated Hospital of China Medical University, Shenyang, China.
Guangping LiDepartment of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, China.ORCID 0000-0003-2121-2873
Suxin LuoDepartment of Cardiology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Shenghua ZhouDepartment of Cardiology, Xiangya No. 2 Hospital Central South University, Changsha, China.
Yang ZhengDepartment of Cardiology, No. 1 Hospital of Jilin University, Changchun, China.
Jie FanDepartment of Cardiology, First People's Hospital of Yunnan Province, Kunming, China.
Xuebin CaoDepartment of Cardiology, The 252 Hospital of Chinese People's Liberation Army, Beijing, China.
Guizhou TaoDepartment of Cardiology, First Affiliated of Liaoning Medical University, Shenyang, China.
Guotai ShengDepartment of Cardiology, Jiangxi Provincial People's Hospital, Nanchang, China.
Zhisheng BaiDepartment of Cardiology, The Department of Cardiology, People's Hospital of Baoji City, Baoji, China.
Shan JiangDepartment of Cardiology, Jinzhou Central Hospital, Jinzhou, China.
Xiaolin LiuDepartment of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Weijuan GuDepartment of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Feng ChenDepartment of Statistics of Nanjing Medical University, Nanjing, China.
Kejiang CaoDepartment of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.ORCID 0000-0002-4542-3811
Jiangsu Province Hospital · CNNanjing Medical University · CN307th Hospital of Chinese People’s Liberation Army · CNBaoji City Central Hospital · CNCentral South University · CNChina Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFirst Affiliated Hospital of Bengbu Medical College · CNFirst People's Hospital of Yunnan Province · CNJiangxi Provincial People's Hospital · CNJilin University · CNJinzhou Central Hospital · CNJinzhou Medical University · CNNanchang University · CNNational University Heart Centre Singapore · SGSecond Hospital of Tianjin Medical University · CNThe Affiliated Yongchuan Hospital of Chongqing Medical University · CNWuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacological antiarrhythmic therapy such as beta-blockers in patients with frequent premature ventricular contractions (PVCs) and concomitant bradycardia is challenging. A traditional Chinese medicine, Shensong Yangxin (SSYX), has been effective in treatment of frequent PVCs and sinus bradycardia (SB) in separate patient cohorts. This double-blind, placebo-controlled, multicentre, randomized clinical trial investigates the acute efficacy of SSYX in reducing PVCs burden in patients with concomitant SB. Patients with symptomatic, frequent PVCs, and SB, defined as mean heart rate (MHR) of 45 to 59 beats per min (bpm), were recruited at 33 medical centres in mainland China and randomly assigned by computer to either SSYX or matching placebo for eight weeks. Patients, investigators, and trial personnel were masked to treatment allocation. Primary endpoints were changes in PVCs burden and MHR as assessed by 24-hour Holter monitoring relative to baseline. Secondary efficacy endpoints were subjective symptom score, ECG, and biochemical parameters. Analysis was based on intention-to-treat principles. 333 patients were randomized, of which 166 received SSYX and 167 placebo. Baseline characteristics did not differ. SSYX reduced PVCs burden by 68.2% (

Identifiers

PMID30949218
PMCPMC6425419
OpenAlexW2919023288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.